A clinical-stage biopharmaceutical company developing novel therapies for heart failure
anacardio.comStockholm, SwedenBiotechFounded 2017
17 sources
KDventures is mentioned in connection with its ownership and a carrying-value adjustment, not as an investor in this financing. The article’s 30 September dateline fixes the announcement day.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $71.0M €100M financing total EUR 62.5m | 2026-09-29 | Ljungström family office, Novo Holdings | No recent discussion |
17 sources [ VERIFIED · CORRECTED ] read against 1 of 17 sources
KDventures is mentioned in connection with its ownership and a carrying-value adjustment, not as an investor in this financing. The article’s 30 September dateline fixes the announcement day. | ||||
AnaCardio AB is a Swedish clinical-stage biopharmaceutical company developing novel drugs, led by oral ghrelin-receptor agonist AC01, to treat heart failure.
Heart failure patients remain underserved, while conventional inotropes can cause arrhythmias, ischaemia, hypotension and increased mortality; AnaCardio is testing AC01 as an oral calcium-sensitizing therapy intended to improve cardiac contractility without those safety concerns. The latest €62.5 million Series B is intended to fund the approximately 400-patient Phase 2b GOAL-HF2 study and advance AC01 toward Phase 3 readiness by 2028, following reported Phase 1b/2a improvements in cardiac output and ejection fraction.
Checked against 10 sources on Sep 30
Also named as backers in company research: Karolinska Development AB, Flerie Invest AB